The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...
Clinical Trials Arena on MSN9d
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosisThe trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Tiziana Life Sciences (NASDAQ:TLSA) recently announced that it submitted its IND of fully human anti-CD3 monoclonal antibody foralumab to begin a phase 2 study for the treatment of patients with ...
A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...
Despite its devastating impact, treatment options remain limited, highlighting the critical importance of advancing research efforts like those undertaken by Tiziana Life Sciences. Ivor Elrifi ...
Tiziana Life Sciences Ltd. NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
[1],[2] Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback